ClinicalTrials.gg
Not yet recruitingNCT07847957Updated Sep 29, 2026

Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL

A Phase 1/2 interventional study of Roginolisib and Obinutuzumab in Chronic Lymphocytic Leukemia (CLL) and Refractory Chronic Lymphocytic Leukemia, sponsored by Dana-Farber Cancer Institute. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Dana-Farber Cancer Institute · Phase 1/2, Interventional, and Treatment

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Dana-Farber Cancer Institute — 6 open to participants now, 11 under way, none of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Dana-Farber Cancer Institute.

Planned enrollment
9th of 17
40 · median 40
Started
2027
the only one that year
Phase 1/2
4 of 21
1 open now
Primary completion
2027-04
later than 6 of 10 live
Registered
21st of 21
by date

Among the 21 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Dana-Farber Cancer Institute, this one is the 9th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2027, is one of 4 in phase 1/2, reaches primary completion later than 6 of the 10 other live ones, and was the 21st registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

6 of the 21 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

This is a Phase 1b and 2, open-label, single-arm study evaluating the safety, tolerability, and efficacy of roginolisib (IOA-244) in combination with obinutuzumab followed by venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have progressed after prior Bruton Tyrosine Kinase (BTK) inhibitor therapy. The study aims to determine the maximum tolerated dose of roginolisib in combination with obinutuzumab, and to assess the rate of undetectable minimal residual disease (uMRD) after sequential therapy with roginolisib, obinutuzumab, and venetoclax.

Read the detailed description

The study consists of two parts: Phase 1b: A safety lead-in using a 3+3 dose escalation design to determine the recommended dose of roginolisib (40 mg or 80 mg QD) in combination with obinutuzumab. After 6 months of combination therapy, venetoclax is added for 6-12 months. DLTs are assessed at the end of cycle 2.

Phase 2: Dose expansion at the recommended phase 2 dose. Participants receive obinutuzumab and roginolisib for 6 months, followed by venetoclax and roginolisib for an additional 6 months. Participants who do not achieve uMRD after 12 months may continue therapy for another 6 months.

All participants will receive roginolisib orally once daily, obinutuzumab intravenously as per label for 6 cycles, and venetoclax orally as per label starting at cycle 7 with standard ramp-up. The primary endpoint is the rate of objective response with uMRD in bone marrow at the end of one year of combination therapy.

Up to 40 patients will be enrolled over 36 months.

03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL)
  • Refractory Chronic Lymphocytic Leukemia

Keywords

  • Chronic Lymphocytic Leukemia (CLL)
  • Relapsed/Refractory CLL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with CLL who meet iwCLL criteria for requiring treatment (Hallek et al. 2018).
  • Participants with as defined by at least one of: circulating lymphocytosis > 5000 B cells/microliter, bone marrow involvement > 30%, palpable splenomegaly or lymph nodes > 1.5 cm. Computer tomography (CT) at screening must be performed and followed every 2 cycles (1 cycle = 28 days)
  • Participants must have received at least one prior therapy for CLL including systemic therapy containing a covalent BTK inhibitor.
  • Participants willing to undergo a pre-treatment and on treatment bone marrow .

Age ≥18 years, at the time of signing the IRB approved . Because no dosing or adverse event data are currently available on the use of venetoclax in combination with roginolisib in participants \<18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.

(ECOG) performance status of ≤ 2.

-Participants must meet the following organ and marrow function as defined below:

  • count ≥50 x 109/L\^\^\^
  • Total ≤ 1.5 ×institutional (ULN)*
  • (SGOT)/ALT(SGPT) ≤3.0 × institutional ULN
  • ≥ 50 mL/min** Thrombocytopenia due to marrow involvement of CLL: > 30 x 109/L

    • unless increase attributed to leukemic organ involvement, hemolysis or Gilbert's syndrome. Participants who are \< 75 years may have bilirubin of ≤ 3.0 × ULN ** calculated by the Cockcroft Gault formula or measured by 24 hours urine collection

Participants with clinically inactive CNS disease or treated CNS disease that is no longer symptomatic, or who need or anticonvulsants may be enrolled in the study. For participants who have symptoms present, imaging and lumbar puncture must be performed to exclude a CNS condition that may impact the study conduct.

Willingness to undergo a pre-treatment and on-treatment bone marrow biopsy to evaluate MRD.

Willingness to use adequate prior to study entry and for the duration of study participation.

  • The effects of roginolisib on the developing human fetus are unknown.
  • Venetoclax may cause embryo fetal harm when administered to pregnant women. Anti-CD20 targeting agents are likely to cause fetal B-cell depletion. For this reason women of and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Women of child-bearing potential will be required to have a negative serum pregnancy test during screening and a negative serum pregnancy test on Cycle 1 Day 1. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of roginolisib or venetoclax administration. Contraception must be conducted up to 12 months after taking the last rituximab dose.

Ability to understand and the willingness to sign a written informed consent document, which includes compliance with the requirements of this protocol.

Eligible to receive infection prophylaxis and supportive care as per institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • Participants who have received prior treatment with venetoclax or PI3K inhibitors in the last 6 months. Participants must not have had any CLL-directed anticancer therapy within 5 half-lives of the therapy prior to Cycle 1 Day 1.

Participants who have received a within 30 days of planned start of study therapy. With regards to other type of vaccines, including SARS-Co2 vaccines, these are allowed

-Participants requiring ongoing treatment with chronic high dose (e.g., cyclosporine) or systemic > 20 mg prednisone (or equivalent) QD. For example, participants with uncontrolled haemolytic anaemia (AIHA) or idiopathic thrombocytopenia purpura (ITP), which requires > 20 mg once daily (QD) of prednisone (or equivalent) to maintain levels of >8.0 g/dL or > 10,000 mL without transfusion support.

History of transformation of CLL to aggressive non-Hodgkin lymphoma (Richter´s transformation or pro-lymphocytic leukaemia) which may otherwise interfere with the interpretation of the outcome of the study (including biomarker evaluation).

  • Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia or fatigue. Any irAEs from prior immunotherapy must have complete resolution and must have resolved at least 2 weeks before Cycle1 Day1.
  • Participants who are receiving any other agents for this condition History of allergic reactions attributed to compounds of similar chemical or biologic composition to roginolisib or venetoclax or their formulation components or prior anti-CD20 targeting agents more than 6 months before initiating study treatments.
  • Participants receiving any medications or substances that are strong inhibitors or inducers of are ineligible. Moderate CYP3A inhibitors and P-gp inhibitors can be administered when venetoclax dose is reduced to 50%. Otherwise, venetoclax is in participants requiring strong or moderate CYP3A inducers.

Because of ongoing research, regularly consulting medical reference databases is recommended. One such reference is the Website of the US-FDA: (Drug Interactions \| Relevant Regulatory Guidance and Policy Documents \| FDA)

As part of the enrollment/ procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.

Pregnant women are excluded from this study because venetoclax has the potential to cause embryo-fetal harm, and the potential for teratogenic or abortifacient effects with roginolisib is currently unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with roginolisib or venetoclax breastfeeding should be discontinued if the mother is treated with these agents.

Participants with a history of other primary are excluded when they require therapy that will interfere with the investigational treatments. Exceptions are if the natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen. For example:

  • Malignancies surgically treated with curative intent and with no known active disease present
  • Adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease
  • Adequately treated cervical carcinoma in situ without evidence of disease.
  • Surgically/adequately treated low-grade, early-stage, localized prostate cancer without evidence of disease or low risk localized prostate cancer on observation.
  • Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications.
  • History or presence of cardiovascular disease, which in the Investigator's opinion may impact the clinical trial participation.
  • History of tuberculosis treatment within the preceding two years.

Ongoing systemic bacterial, fungal, or viral infections (including also hepatitis viral infection) at the time of initiation of study treatment (defined as requiring intravenous [IV] antimicrobial, antifungal or antiviral agents). Subjects on antimicrobial, antifungal or antiviral prophylaxis are not specifically excluded if all other inclusion/exclusion criteria are met, there is no evidence of active infection at enrollment, and ongoing treatment does not have a significant risk of drug-drug interaction with venetoclax.

Known (HIV) infection which is treated with agents that can interfere with venetoclax due to potential drug-drug interactions or increased risk of myelotoxicity.

Any serious or uncontrolled medical disorder or active infection that, in the opinion of the Investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the participant to receive protocol therapy.

Known alcohol or substance abuse.

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Roginolisib + Obinutuzumab followed by Roginolisib + Venetoclax

    All participants receive roginolisib orally once daily in the morning, obinutuzumab intravenously as per label for 6 cycles, and venetoclax orally as per label starting at cycle 7 with standard ramp-up.

    Drug: Roginolisib · Drug: Obinutuzumab · Drug: Venetoclax

Interventions

  • Oral, once daily, 40 mg or 80 mg QD depending on cohort, starting on day 1 of cycle 1 and continuing until cycle 13 or until progression/toxicity.

    Also known as: IOA-244

  • Intravenous infusion, administered as per label for 6 cycles (28-day cycles): 100 mg on day 1 cycle 1, 900 mg on day 2 cycle 1, 1000 mg on days 8 and 15 of cycle 1, then 1000 mg on day 1 of cycles 2-6.

  • Oral, once daily, starting at cycle 7 with standard weekly dose escalation (20 mg, 50 mg, 100 mg, 200 mg, 400 mg), then continued for 6-12 months depending on MRD results.

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Dose-Limiting Toxicities (DLT) [Phase Ib]

    DLT is defined according to NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0, including grade 4 neutropenia lasting \>7 days, febrile neutropenia, grade ≥3 thrombocytopenia with clinically significant bleeding, grade ≥4 infection, grade ≥3 non-hematologic toxicity (with protocol-specified exceptions), grade ≥3 diarrhea, severe cutaneous reactions (grade ≥3), significant hepatic toxicity, inability to initiate Cycle 2 within 14 days due to treatment-related toxicity, and grade 5 adverse events not clearly attributable to the underlying disease.

    Time frame: Up to 2 months

Secondary outcomes

  1. Objective Response Rate (ORR) With Undetectable Minimal Residual Disease (uMRD) [Phase II]

    ORR with uMRD is defined as the proportion of participants who achieve a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR), or partial response (PR) according to 2018 iwCLL criteria and undetectable minimal residual disease (uMRD), defined as fewer than 1 CLL cell per 10,000 leukocytes in bone marrow as assessed by clonoSEQ (10-⁴ sensitivity).

    Time frame: At the end of 1 year of combination therapy.

  2. Non-hematologic Toxicity Rate [Phase II]

    Non-hematologic toxicity rate is defined as the proportion of participants experiencing non-hematologic toxicities graded according to NCI CTCAE version 5.0.

    Time frame: Up to 18 months. Adverse events are assessed on Days 1, 2, 8, and 15 of Cycles 1 and 7 and on Day 1 of all other cycles; each cycle is 28 days.

  3. Hematologic Toxicity Rate [Phase II]

    Hematologic toxicity rate is defined as the proportion of participants experiencing hematologic toxicities according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria.

    Time frame: Up to 18 months. Adverse events are assessed on Days 1, 2, 8, and 15 of Cycles 1 and 7 and on Day 1 of all other cycles; each cycle is 28 days.

  4. uMRD Rate [Phase II]

    uMRD rate is defined as the proportion of participants with undetectable minimal residual disease, defined as fewer than 1 CLL cell per 10,000 leukocytes, in peripheral blood and bone marrow as assessed by flow cytometry.

    Time frame: At the end of treatment (up to 18 months).

  5. Median Progression-Free Survival (PFS) [Phase II]

    PFS based on Kaplan-Meier method is defined as the time from study registration to disease progression (PD) or death from any cause, whichever occurs first. Participants without documented disease progression or death will be censored at the date of their last disease assessment. PD according to 2018 iwCLL criteria is defined as the appearance of new disease sites, a ≥50% increase in previously involved disease sites or circulating lymphocyte count, Richter transformation, or development of CLL-related neutropenia, anemia, or thrombocytopenia.

    Time frame: Assessed at baseline and on Day 1 of Cycle 2 and subsequent cycles (each cycle is 28 days) during treatment (up to 18 months). Assessments will then performed every 2 months for 3 years and every 4 months for an additional 2 years (total of 5 years).

  6. ORR [Phase II]

    ORR is defined as the proportion of participants who achieve a CR, CRi, nPR, or PR according to 2018 iwCLL criteria.

    Time frame: Assessed at baseline and on Day 1 of Cycle 2 and subsequent cycles (each cycle is 28 days), up to 18 months.

  7. Complete Response Rate (CRR) [Phase II]

    CRR is defined as the proportion of participants who achieve a CR or CRi during treatment according to 2018 iwCLL criteria.

    Time frame: Assessed at baseline and on Day 1 of Cycle 2 and subsequent cycles (each cycle is 28 days), up to 18 months.

  8. Duration of Remission (DOR) [Phase II]

    DOR based on Kaplan-Meier method is defined as the time from first achivement of CR, Cri, nPR, or PR to PD according to 2018 iwCLL criteria. PD is defined as the appearance of new disease sites, a ≥50% increase in previously involved disease sites or circulating lymphocyte count, Richter transformation, or development of CLL-related neutropenia, anemia, or thrombocytopenia.

    Time frame: Assessed at baseline and on Day 1 of Cycle 2 and subsequent cycles (each cycle is 28 days) during treatment (up to 18 months). Assessments will then performed every 2 months for 3 years and every 4 months for an additional 2 years (total of 5 years).

  9. Median Overall Survival (OS) [Phase II]

    OS based on Kaplan-Meier method is defined as the time from study registration to death from any cause. Participants who are alive at the time of analysis will be censored at the date they were last known to be alive.

    Time frame: Assessed every 2 months for 3 years and every 4 months for an additional 2 years after completion of the 18-month treatment period.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — The Harvard Cancer Consortium encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer office for Dana -Farber Innovations (BODFI) at innovations@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Apr 2027, 2 months later.

Of 40 non-industry phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 103. This study's planned 2 months is below that.

Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Sep 29, 2026
StartEst.
Jan 13, 2027
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847957
Collaborators
iOnctura
Responsible party
Jennifer R. Brown, MD, PhD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Sep 29, 2026
Start date
Jan 13, 2027 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Hang Phan
Contact
hang_phan@dfci.harvard.edu
857-215-1258
Jennifer Brown, MD, PhD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roginolisib

Start the discussion